Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1638
This examiner grants 55% of resolved cases
Fatimah Khalaf Matalkah has resolved 42 cases in Art Unit 1638, resulting in an allowance rate of 54.8%. The median days to allowance is quite high at 1328. This suggests a prolonged prosecution cycle in Tech Center 1600. The interview lift is 28.6%, which significantly improves the 54.8% baseline. This 28.6% lift suggests that interviews are a critical strategy for navigating the 1328-day median pendency.
With 42 resolved cases, the lift is a key takeaway for practitioners. The 54.8% allowance rate indicates a moderate probability of success. Applicants should prepare for a 1328-day path to resolution. The 28.6% lift shows that direct communication is highly effective with this examiner. In Art Unit 1638, the 1328-day median is a significant hurdle that requires careful planning.
In Tech Center 1600, the 54.8% rate serves as the primary benchmark. The 28.6% interview lift is one of the most impactful metrics in this profile. By utilizing the 1328-day median as a guide, practitioners can better manage expectations for their clients. The 42 cases provide a developing but clear picture of the examiner's responsiveness to interviews.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17793287 | INDUCIBLE TISSUE CONSTRUCTS AND USES THEREOF | Final Rejection | TRUSTEES OF BOSTON UNIVERSITY |
| 18412130 | CELL CULTURE METHOD, CELL CULTURE CONTAINER, METHOD FOR PRODUCING CELL CULTURE CONTAINER, AND CELL-CONTAINING STRUCTURE | Final Rejection | RICOH COMPANY, LTD. |
| 18332380 | GENERATION OF NEXT GENERATION RECOMBINANT AAV GENE THERAPY VECTORS THAT ADOPT 3D CONFORMATION | Final Rejection | WISCONSIN ALUMNI RESEARCH FOUNDATION |
| 18566782 | ASSAY FOR EXTRINSIC INHIBITION | Non-Final OA | The Regents of The University of California |
| 18278771 | EXTRACELLULAR VESICLES DERIVED FROM INDUCED PLURIPOTENT AND EMBRYONIC STEM CELLS, AND METHODS OF USE FOR IMMUNE MODULATION | Final Rejection | The Regents of the University of California |
| 17911306 | COMPOSITIONS AND METHODS FOR PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS | Final Rejection | The Regents of the University of California |
| 18559921 | ANELLOVECTORS AND METHODS OF USE | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS V, INC. |
| 18720003 | ANTI-FIBROUS CELLS, MEDICAMENT COMPRISING THE CELLS, AND METHOD FOR OBTAINING THESE CELLS | Non-Final OA | B. Braun Avitum AG |
| 17782252 | ADOPTIVE CELL THERAPY WITH ZBTB20 SUPPRESSION | Final Rejection | THE TRUSTEES OF DARTMOUTH COLLEGE |
| 18557033 | ADENO-ASSOCIATED VIRAL VECTORS FOR TRANSDUCTION OF COCHLEA | Non-Final OA | THE CHILDREN'S HOSPITAL OF PHILADELPHIA |
| 17907171 | REPORTER SYSTEM FOR RADIONUCLIDE IMAGING | Non-Final OA | Erasmus University Medical Center Rotterdam |
| 18653905 | METHODS FOR CONTROLLING BLEEDING IN A SUBJECT AFFLICTED WITH HERMANSKY PUDLAK SYNDROME USING PLATELET DERIVATIVE COMPOSITIONS | Non-Final OA | Cellphire, Inc. |
| 18413896 | VECTORS ENCODING GENE EDITING SYSTEMS AND USES THEREOF | Non-Final OA | Mammoth Biosciences, Inc. |
| 18264104 | GENE THERAPY FOR RETINAL DISEASES | Non-Final OA | Greffex, Inc. |
| 17927078 | Lentiviral System | Non-Final OA | Expression Therapeutics, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy